Patent application number | Description | Published |
20110150834 | CRTH2 MODULATORS - Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by formula I: | 06-23-2011 |
20110311483 | CRTH2 MODULATORS - Compounds of Formulae I-1 to I-9 are disclosed, which are modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders. | 12-22-2011 |
20130029970 | CB Receptor Agonists - The present disclosure relates to compounds of formula I useful as agonists of cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders. | 01-31-2013 |
20130109721 | FAAH Inhibitors | 05-02-2013 |
20130178453 | Cannabinoid Agonists - The present disclosure relates to compounds useful as agonists of the cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders, either alone or in combination therapy. The compounds of the invention have Formula (I). | 07-11-2013 |
20150175599 | FAAH Inhibitors - The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders. Compounds of the invention are described in Table 1. | 06-25-2015 |
Patent application number | Description | Published |
20100069762 | System And Method For Assessing Sleep Quality - An assessment of sleep quality and sleep disordered breathing is determined from cardiopulmonary coupling between two physiological data series. An R-R interval series is derived from an electrocardiogram (ECG) signal. The normal beats from the R-R interval series are extracted to produce a normal-to-normal interval series. The amplitude variations in the QRS complex are used to extract a surrogate respiration signal (i.e., ECG-derived respiration) associated with the NN interval series. The two series are corrected to remove outliers, and resampled. The cross-spectral power and coherence of the two resampled signals are calculated over a plurality of coherence windows. For each coherence window, the product of the coherence and cross-spectral power is used to calculate coherent cross-power. Using the appropriate thresholds for the coherent cross-power, the proportion of sleep spent in CAP, non-CAP, and wake and/or REM are determined. Coherent cross-power can be applied to differentiate obstructive from non-obstructive disease, and admixtures of the same. | 03-18-2010 |
20150162009 | ANALYSIS SYSTEM AND METHOD THEREOF - The present invention provides an analysis system adapted for processing a signal with a time period. The analysis system comprises a segmenting unit, an analyzing unit, processing unit and an outputting unit. The segmenting unit divides the signal into a plurality of scale windows according to one of interval scales. The analyzing unit processes the scale windows via HHT algorithm to make each scale window generate a plurality of quantized windows according to different components. The processing unit reorganizes the quantized windows make each scale window generate a plurality of quantized windows according to different components. The outputting unit accumulates a plurality of specific frequency values in difference interval scales and combines the specific frequency values to form a three-dimensional variation visual diagram. | 06-11-2015 |
20150193376 | METHOD OF MULTI-SCALES INTRINSIC ENTROPY ANALYSIS - This invention discloses a multi-scales intrinsic entropy analysis method that can quantify the entropies on difference time scales for a complex time series. The implementation of the method decomposes a complex time series into a plurality of intrinsic mode functions by a nonlinear signal processing algorithm, such as the method of empirical mode decomposition. Then, the entropy increments can be calculated on multiple coarse-graining scales when an intrinsic mode functions is added into the reconstructed time series analyzed by the method of multi-scale entropy. The entropy increment is significant on a specific coarse-graining scale, which corresponds to the averaged period of the intrinsic mode functions. The entropy increment on the specific coarse-graining scale is defined as the intrinsic entropy for an intrinsic mode functions. Multiple intrinsic entropies represent the entropy properties for a complex time series on their corresponding time scales. | 07-09-2015 |
Patent application number | Description | Published |
20090005359 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 01-01-2009 |
20090036419 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 02-05-2009 |
20120040951 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 02-16-2012 |
20130065858 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 03-14-2013 |
20150080568 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 03-19-2015 |
20150203515 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS - Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). | 07-23-2015 |
20150210647 | ATX MODULATING AGENTS - Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer. | 07-30-2015 |
20150361029 | S1P MODULATING AGENTS - Compounds of formula (I) can modulate the activity of one or more S 1P receptors. Sphingosine 1-phosphate (S IP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family, namely S1P1, S1P2, S1P3, S1P4, and S1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDG8). The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (Ga.) subunits and beta-gamma (G( )y) dimers. | 12-17-2015 |
Patent application number | Description | Published |
20110070645 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF PDX1+ PANCREATIC CELLS - Certain embodiments disclosed herein are directed to a method of producing pancreatic cells or pancreatic cell precursors by exposing human embryonic stem cells to an effective amount of at least one compound listed in Table I to differentiate the human embryonic stem cells into the pancreatic cells or the pancreatic cell precursors. Kits and pancreatic cell lines produced using the methods are also described. | 03-24-2011 |
20110172233 | SONIC HEDGEHOG MODULATORS - The present invention relates to relates to macrocyclic small molecule inhibitors of the Sonic Hedgehog signaling pathway, syntheses thereof, and intermediates thereto. Such small molecule modulators of the Sonic Hedgehog signaling pathway are useful in the treatment of proliferative diseases (e.g., basal cell carcinoma, Gorlin syndrome, medulloblastoma, or pancreatic cancer), pulmonary diseases (e.g., interstitial pnuemonitis or interstitial pulmonary fibrosis), and developmental disorders (e.g., phocomelia or cyclopia). Novel non-natural macrocycles are provided that inhibit Sonic Hedgehog induced-protein transcription. | 07-14-2011 |
20120094939 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS AND METHODS - The present invention is directed to compounds of formulae (I) and (II) and pharmaceutically acceptable forms thereof; pharmaceutical compositions thereof; and methods of treating a viral infection, such as a hepatitis C virus (HCV) infection, by administering to a subject diagnosed with or being susceptible to the viral infection a compound of formulae (I) and (II), a pharmaceutically acceptable form thereof, or a pharmaceutical composition thereof. The present invention is also directed to high-throughput methods of identifying compounds able to modulate hepatitis C virus (HCV) replication activity. | 04-19-2012 |
20140335611 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF PDX1+ PANCREATIC CELLS - Certain embodiments disclosed herein are directed to a method of producing pancreatic cells or pancreatic cell precursors by exposing human embryonic stem cells to an effective amount of at least one compound listed in Table I to differentiate the human embryonic stem cells into the pancreatic cells or the pancreatic cell precursors. Kits and pancreatic cell lines produced using the methods are also described. | 11-13-2014 |
Patent application number | Description | Published |
20110064695 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
20110064696 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
20110064697 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
20110064698 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
20110070196 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-24-2011 |
20110070197 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-24-2011 |
20110142798 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-16-2011 |
20110189129 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 08-04-2011 |
20110250172 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-13-2011 |
20110300104 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 12-08-2011 |
20120039848 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-16-2012 |
20120076755 | Hepatitis C Virus Inhibitors - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-29-2012 |
20120076756 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-29-2012 |
20130295049 | LINKED DIBENZIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-07-2013 |
20140187793 | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO[2.4]HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES - The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (Ia), (Ib) and (Ic): | 07-03-2014 |
20140193363 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-10-2014 |
20140308243 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-16-2014 |
20140316143 | PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a): | 10-23-2014 |
20140341851 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-20-2014 |